Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1989 Sep;77(3):391–396.

Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis.

J L Macpherson 1, A Kemp 1, M Rogers 1, A I Mallet 1, R F Toia 1, B Spur 1, J W Earl 1, C N Chesterman 1, S A Krilis 1
PMCID: PMC1542063  PMID: 2805409

Abstract

We have identified PAF in the blister fluid from a patient with bullous mastocytosis, a rare form of mast-cell disease. We have found a novel endogenous inhibitor of platelet aggregation which obscured the presence of the PAF in unprocessed blister fluid and in ethanol or lipid extracts. The PAF was characterized by the demonstration of chromatographic, mass spectral and biological properties identical to those of authentic PAF. Thus this is the first demonstration of PAF in biological fluid from a patient with mastocytosis. High levels of immunoreactive prostaglandin D2 (PGD2) and histamine were also present in the blister fluid. The interaction between PAF and the inhibitor of platelet aggregation in patients with systemic mastocytosis may provide an explanation for some of the manifestations of the disease, in particular the episodic hypotension, cutaneous flushing and pallor.

Full text

PDF
391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer C. B., Page C. P., Morley J., MacDonald D. M. Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man. Br J Dermatol. 1985 Mar;112(3):285–290. doi: 10.1111/j.1365-2133.1985.tb04855.x. [DOI] [PubMed] [Google Scholar]
  2. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  3. Basran G. S., Page C. P., Paul W., Morley J. Cromoglycate (DSCG) inhibits responses to platelet-activating factor (PAF-acether) in man: an alternative mode of action for DSCG in asthma? Eur J Pharmacol. 1982 Dec 17;86(1):143–144. doi: 10.1016/0014-2999(82)90415-0. [DOI] [PubMed] [Google Scholar]
  4. Bushfield M., McNicol A., MacIntyre D. E. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. Biochem J. 1985 Nov 15;232(1):267–271. doi: 10.1042/bj2320267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Camussi G., Mencia-Huerta J. M., Benveniste J. Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology. 1977 Oct;33(4):523–534. [PMC free article] [PubMed] [Google Scholar]
  6. Chesney C. M., Pifer D. D., Byers L. W., Muirhead E. E. Effect of platelet-activating factor (PAF) on human platelets. Blood. 1982 Mar;59(3):582–585. [PubMed] [Google Scholar]
  7. Chesterman C. N., Owe-Young R., Macpherson J., Krilis S. A. Substrate for endothelial prostacyclin production in the presence of platelets exposed to collagen is derived from the platelets rather than the endothelium. Blood. 1986 Jun;67(6):1744–1750. [PubMed] [Google Scholar]
  8. Golitz L. E., Weston W. L., Lane A. T. Bullous mastocytosis: diffuse cutaneous mastocytosis with extensive blisters mimicking scalded skin syndrome or erythema multiforme. Pediatr Dermatol. 1984 Apr;1(4):288–294. doi: 10.1111/j.1525-1470.1984.tb01131.x. [DOI] [PubMed] [Google Scholar]
  9. Guinot P., Summerhayes C., Berdah L., Duchier J., Revillaud R. J. Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063. Lancet. 1988 Jul 9;2(8602):114–114. doi: 10.1016/s0140-6736(88)90055-4. [DOI] [PubMed] [Google Scholar]
  10. Jackson E. M., Mott G. E., Hoppens C., McManus L. M., Weintraub S. T., Ludwig J. C., Pinckard R. N. High performance liquid chromatography of platelet-activating factors. J Lipid Res. 1984 Jul;25(7):753–757. [PubMed] [Google Scholar]
  11. Joly F., Bessou G., Benveniste J., Ninio E. Ketotifen inhibits paf-acether biosynthesis and beta-hexosaminidase release in mouse mast cells stimulated with antigen. Eur J Pharmacol. 1987 Dec 1;144(2):133–139. doi: 10.1016/0014-2999(87)90511-5. [DOI] [PubMed] [Google Scholar]
  12. Keyzer J. J., de Monchy J. G., van Doormaal J. J., van Voorst Vader P. C. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med. 1983 Dec 29;309(26):1603–1605. doi: 10.1056/NEJM198312293092603. [DOI] [PubMed] [Google Scholar]
  13. Miwa M., Hill C., Kumar R., Sugatani J., Olson M. S., Hanahan D. J. Occurrence of an endogenous inhibitor of platelet-activating factor in rat liver. J Biol Chem. 1987 Jan 15;262(2):527–530. [PubMed] [Google Scholar]
  14. Morley J., Page C. P., Mazzoni L., Sanjar S. Effects of ketotifen upon responses to platelet activating factor: a basis for asthma prophylaxis. Ann Allergy. 1986 Apr;56(4):335–340. [PubMed] [Google Scholar]
  15. Page C. P., Tomiak R. H., Sanjar S., Morley J. Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. Agents Actions. 1985 Mar;16(1-2):33–35. doi: 10.1007/BF01999637. [DOI] [PubMed] [Google Scholar]
  16. Roberts L. J., 2nd, Sweetman B. J., Lewis R. A., Austen K. F., Oates J. A. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med. 1980 Dec 11;303(24):1400–1404. doi: 10.1056/NEJM198012113032405. [DOI] [PubMed] [Google Scholar]
  17. Roberts L. J., 2nd, Sweetman B. J. Metabolic fate of endogenously synthesized prostaglandin D2 in a human female with mastocytosis. Prostaglandins. 1985 Sep;30(3):383–400. doi: 10.1016/0090-6980(85)90114-5. [DOI] [PubMed] [Google Scholar]
  18. Ruzicka T., Simmet T., Peskar B. A., Ring J. Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J Invest Dermatol. 1986 Feb;86(2):105–108. doi: 10.1111/1523-1747.ep12284061. [DOI] [PubMed] [Google Scholar]
  19. Soter N. A., Austen K. F., Wasserman S. I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med. 1979 Aug 30;301(9):465–469. doi: 10.1056/NEJM197908303010903. [DOI] [PubMed] [Google Scholar]
  20. Tencé V., Polonsky J., Le Couedic J. P., Benveniste M. J. Release, purification, and characterization of platelet-activating factor (PAF). Biochimie. 1980;62(4):251–259. doi: 10.1016/s0300-9084(80)80399-3. [DOI] [PubMed] [Google Scholar]
  21. Turnell D. C., Cooper J. D. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clin Chem. 1982 Mar;28(3):527–531. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES